Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tetroxoprim
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Tetroxoprim is a synthetic antibiotic of the diaminopyrimidine class and a structural derivative of trimethoprim. It acts as a selective inhibitor of bacterial dihydrofolate reductase, thereby disrupting folate synthesis in bacteria and inhibiting DNA and RNA production. Tetroxoprim has been used experimentally, often in combination with sulfadiazine (as co-tetroxazine), for the treatment of susceptible bacterial infections[2][3][5][7][8].
- Other names
- tetroxoprimatetroxoprimetetroxoprimum
02
Targets
DHFR-TS (Bifunctional dihydrofolate reductase-thymidylate synthase)
Beyond the preview
Go deeper on tetroxoprim.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tetroxoprim.